Xenon Pharmaceuticals has filed a patent for compounds of formula (I) that can be used as voltage-gated sodium channel modulators to treat seizure disorders like epilepsy. The compounds can exist as stereoisomers, enantiomers, or tautomers, and can also be in the form of pharmaceutically acceptable salts, solvates, or prodrugs. The patent claim is for a compound of formula (I). GlobalData’s report on Xenon Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Xenon Pharmaceuticals, human telomerase RT biomarker was a key innovation area identified from patents. Xenon Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230203007A1) describes a compound of formula (I) and its various derivatives, stereoisomers, enantiomers, tautomers, mixtures, and pharmaceutically acceptable forms. The compound has potential applications in the treatment of diseases or conditions modulated by voltage-gated sodium channels.
The compound of formula (I) is defined by the presence of X, R1, R2, R3, R3a, and R4, each with specific characteristics as outlined in the patent claims. These characteristics include the presence of various functional groups such as halo, alkyl, haloalkyl, cyano, heterocyclylalkyl, —R8—N(R9)2, —R8—C(-O)N(R9)2, or —R8—OR9. Additionally, R1 can be N or —Si(CH3)3, and R2, R3, R3a, and R4 can have specific structures or functional groups.
The patent also describes the use of the compound of formula (I) in pharmaceutical compositions, which may include a pharmaceutically acceptable excipient. These compositions can be used for the treatment of diseases or conditions in mammals that are modulated by voltage-gated sodium channels. The method involves administering a therapeutically effective amount of the compound to the mammal in need.
Overall, this patent provides a detailed description of a compound of formula (I) and its derivatives, as well as their potential applications in the treatment of diseases or conditions modulated by voltage-gated sodium channels. The compound's various forms, including stereoisomers, enantiomers, tautomers, mixtures, and pharmaceutically acceptable salts, solvates, or prodrugs, are also discussed. The patent further highlights the use of the compound in pharmaceutical compositions and its potential as a therapeutic agent for mammals.
To know more about GlobalData’s detailed insights on Xenon Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
